Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
The Pharma Data
DECEMBER 21, 2020
Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.
40 
Let's personalize your content